• 403. I-CAN, A Study of Inebilizumab in Children with AQP4+ NMOSD

  • Sep 6 2023
  • Duración: 16 m
  • Podcast
403. I-CAN, A Study of Inebilizumab in Children with AQP4+ NMOSD Por arte de portada

403. I-CAN, A Study of Inebilizumab in Children with AQP4+ NMOSD

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • For this “ABCs of NMOSD” episode, Rebecca Whitney of SRNA was joined by Dr. Michael Levy. Dr. Levy gave an overview of I-CAN, a Phase 2 study of inebilizumab in children with aquaporin-4 positive neuromyelitis optica spectrum disorder or NMOSD. As one of the principal investigators for the study, he shared details about inclusion criteria and inebilizumab, brand name Uplizna™. Dr. Levy also discussed what someone can expect if they choose to participate in this trial, how participation would impact someone’s current treatment, and the timeline of this trial. Additional information is available here:

    https://wearesrna.org/clinical-studies-and-trials/study-of-inebilizumab-in-pediatric-subjects-with-neuromyelitis-optica-spectrum-disorder/ 

    https://clinicaltrials.gov/study/NCT05549258?term=NCT05549258&aggFilters=status:not%20rec&rank=1
    Más Menos
Más Menos

Lo que los oyentes dicen sobre 403. I-CAN, A Study of Inebilizumab in Children with AQP4+ NMOSD

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles